Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: A novel anti-cancer treatment avenue?

Cancer Immunology, Immunotherapy

Volumn 63, Issue 7, 2014, Pages 643-662

  Siliņa, Karina ^a   Rulle, Undine ^a   Kalniņa, Zane ^a   Lině, Aija ^a  

^a LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

Author keywords

Cancer immunotherapy; Cancer therapy; Tertiary lymphoid structures; Tumour infiltrating B cells

Indexed keywords

AUTOANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; INTERLEUKIN 10;

ADOPTIVE TRANSFER; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL INFILTRATION; CELLULAR IMMUNITY; COLORECTAL CANCER; CUTANEOUS MELANOMA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EMBRYO DEVELOPMENT; FOLLICULAR DENDRITIC CELL; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MALIGNANT MESOTHELIOMA; MELANOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PERSISTENT INFECTION; PHENOTYPE; PLASMA CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; REVIEW; TH1 CELL; TH2 CELL; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; B-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; PROGNOSIS;

EID: 84903818166     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1544-9     Document Type: Review

References (179)

1. Ramakrishnan R, Gabrilovich DI (2013) Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother 62(3):405-410. doi:10.1007/s00262-012-1390-6
2. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18(5):1386-1394. doi:10.1158/1078-0432.CCR-11-2479
3. Coventry BJ, Ashdown ML (2012) Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res 4:137-149. doi:10.2147/CMAR.S31887
4. Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR (2012) The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 39(3):323-339. doi:10.1053/j.seminon col.2012.02.006
5. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71(17):5601-5605. doi:10.1158/0008-5472.CAN-11-1316
6. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. NatRev Cancer 12(4):298-306. doi:10.1038/nrc3245
7. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, Itoh K (1990) Patterns of human tumorinfiltrating lymphocytes in 120 human cancers. Arch Surg 125(2):200-205. doi:10.1001/archsurg.1990.01410140078012 (Pubitemid 20060644)
8. Schoorl R, Riviere AB, Borne AE, Feltkamp-Vroom TM (1976) Identification of T and B lymphocytes in human breast cancer with immunohistochemical techniques. Am J Pathol 84(3):529-544
9. Jackson PA, Green MA, Marks CG, King RJ, Hubbard R, Cook MG (1996) Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. Gut 38(1):85-89. doi:10.1136/gut.38.1.85 (Pubitemid 26020934)
10. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pages F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782-795. doi:10.1016/j.immuni.2013.10.003
11. Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K (1982) Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T- and B-cell sera. Cancer 49(7):1456-1464. doi:10.1002/1097-0142(19820401)49:7〈1456::AID- CNCR2820490724〉3.0.CO;2-# (Pubitemid 12143070)
12. Monach PA, Schreiber H, Rowley DA (1993) CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 55(6):1356-1361 (Pubitemid 23183251)
13. Brodt P, Gordon J (1978) Anti-tumor immunity in B lympho-cyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol 121(1):359-362 (Pubitemid 8384890)
14. Kammertoens T, Qin Z, Briesemeister D, Bendelac A, Blankenstein T (2012) B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-alpha, perforin). Int J Cancer 131(7):1499-1508. doi:10.1002/ijc.27411
15. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR (2011) B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci USA 108(26):10662-10667. doi:10.1073/pnas.1100994108
16. de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7(5):411-423. doi:10.1016/j.ccr.2005.04.014 (Pubitemid 40719125)
17. Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C (2013) B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology 2(7):e25443. doi:10.4161/onci.25443
18. Wu CW, Wang SY, Chiang H, Lui WY, P'Eng FK, Ho CK (1992) Functional capacity of a tumor-infiltrating B-cell line: lymphokine secretion. Immunol Res 11(1):34-41. doi:10.1007/BF02918606
19. Katano M, Kubota E, Nagumo F, Matsuo T, Hisatsugu T, Tadano J (1994) Inhibition of tumor cell growth by a human B-cell line. Biotherapy 8(1):1-6. doi:10.1007/BF01878115
20. Qin Z, Blankenstein T (1995) Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response. Cancer Res 55(21):4747-4751
21. Lopez DM, Blomberg BB, Padmanabhan RR, Bourguignon LY (1989) Nuclear disintegration of target cells by killer B lymphocytes from tumor-bearing mice. FASEB J 3(1):37-43 (Pubitemid 19042563)
22. Norimov A, Khaitov RM, Gambarov SS (1976) Functional activity of splenic T- and B-cells during the process of tumor growth. Biull Eksp Biol Med 82(12):1475-1477
23. Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD (1986) Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 95(2):142-152 (Pubitemid 16025387)
24. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Muller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenfuhrer J, Hengstler JG (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18(9):2695-2703. doi:10.1158/1078-0432.CCR- 11-2210
25. Richards CH, Flegg KM, Roxburgh CS, Going JJ, Mohammed Z, Horgan PG, McMillan DC (2012) The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer 106(12):2010-2015. doi:10.1038/bjc.2012.211
26. Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD (2013) Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol 14(4):R34. doi:10.1186/gb-2013-14-4-r34
27. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68(13):5405-5413. doi:10.1158/0008-5472.CAN-07-5206
28. Schmidt M, Micke P, Gehrmann M, Hengstler JG (2012) Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors. Oncoimmunology 1(7):1156-1158. doi:10.4161/onci.21653
29. Chen Z, Gerhold-Ay A, Gebhard S, Boehm D, Solbach C, Lebrecht A, Battista M, Sicking I, Cotarelo C, Cadenas C, Marchan R, Stewart JD, Gehrmann M, Koelbl H, Hengstler JG, Schmidt M (2012) Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS ONE 7(9):e44741. doi:10.1371/journal.pone.0044741
30. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132(2):545-553. doi:10.1007/s10549-011-1620-1
31. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, Bear HD, Marincola FM, Manjili MH (2012) A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 131(3):871-880. doi:10.1007/s10549-011-1470-x
32. Nelson BH (2010) CD20 + B cells: the other tumor-infiltrating lymphocytes. J Immunol 185(9):4977-4982. doi:10.4049/jimmu nol.1001323
33. Namm JP, Li Q, Lao X, Lubman DM, He J, Liu Y, Zhu J, Wei S, Chang AE (2012) B lymphocytes as effector cells in the immunotherapy of cancer. JSurgOncol 105(4):431-435
34. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, Johnson LL, Swain SL, Lund FE (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. NatImmunol 1(6):475-482. doi:10.1038/82717
35. Lund FE, Randall TD (2010) Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 10(4):236-247. doi:10.1038/nri2729
36. Gray D, Gray M, Barr T (2007) Innate responses of B cells. Eur J Immunol 37(12):3304-3310. doi:10.1002/eji.200737728
37. Whitmire JK, Asano MS, Kaech SM, Sarkar S, Hannum LG, Shlomchik MJ, Ahmed R (2009) Requirement of B cells for generating CD4+ T cell memory. J Immunol 182(4):1868-1876. doi:10.4049/jimmunol.0802501
38. Deola S, Panelli MC, Maric D, Selleri S, Dmitrieva NI, Voss CY, Klein H, Stroncek D, Wang E, Marincola FM (2008) Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J Immunol 180(3):1362-1372
39. Vadasz Z, Haj T, Kessel A, Toubi E (2013) B-regulatory cells in autoimmunity and immune mediated inflammation. FEBS Lett 587(13):2074-2078. doi:10.1016/j.febslet.2013.05.023
40. Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN (2012) Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol 33(6):297-305. doi:10.1016/j.it.2012.04.006
41. Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP (2001) Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res 61(21):7889-7899 (Pubitemid 33050986)
42. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169(4):1829-1836 (Pubitemid 34857644)
43. Hansen MH, Nielsen HV, Ditzel HJ (2002) Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 169(5):2701-2711 (Pubitemid 34921019)
44. Hansen MH, Nielsen H, Ditzel HJ (2001) The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 98(22):12659-12664. doi:10.1073/pnas.171460798 (Pubitemid 33020002)
45. Nzula S, Going JJ, Stott DI (2003) Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 63(12):3275-3280 (Pubitemid 36735883)
46. Pavoni E, Monteriu G, Santapaola D, Petronzelli F, Anastasi AM, Pelliccia A, D'Alessio V, De Santis R, Minenkova O (2007) Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. BMC Biotechnol 7:70. doi:10.1186/1472-6750-7-70
47. Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, Glassy MC (2005) Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol 175(4):2278-2285 (Pubitemid 41113835)
48. Simsa P, Teillaud JL, Stott DI, Toth J, Kotlan B (2005) Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma. Pathol Oncol Res 11(2):92-97 (Pubitemid 41039445)
49. Maletzki C, Jahnke A, Ostwald C, Klar E, Prall F, Linnebacher M (2012) Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG. PLoS ONE 7(2):e32639. doi:10.1371/journal.pone.0032639
50. Wu H, Pancook JD, Beuerlein G, Chilton T, Pecht G, Huse WD, Watkins JD (2002) Cloning, isolation and characterization of human tumor in situ monoclonal antibodies. Cancer Immunol Immunother 51(2):79-90. doi:10.1007/s00262-001-0258- y (Pubitemid 34230722)
51. Wang Y, Ylera F, Boston M, Kang SG, Kutok JL, Klein-Szanto AJ, Junghans RP (2007) Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. Breast Cancer Res Treat 104(2):129-144. doi:10.1007/s10549-006-9409-3 (Pubitemid 47084230)
52. Yasuda M, Takenoyama M, Obata Y, Sugaya M, So T, Hanagiri T, Sugio K, Yasumoto K (2002) Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer. Cancer Res 62(6):1751-1756 (Pubitemid 34408498)
53. Imahayashi S, Ichiyoshi Y, Yoshino I, Eifuku R, Takenoyama M, Yasumoto K (2000) Tumor-infiltrating B-cell-derived IgG recognizes tumor components in human lung cancer. Cancer Invest 18(6):530-536 (Pubitemid 30485669)
54. O'Brien PM, Millan DW, Davis JA, Campo MS (2005) In situ isolation of immunoglobulin sequences expressed by single tumor-infiltrating B cells using laser-assisted microdissection. Mol Biotechnol 29(2):101-109
55. Willis SN, Mallozzi SS, Rodig SJ, Cronk KM, McArdel SL, Caron T, Pinkus GS, Lovato L, Shampain KL, Anderson DE, Anderson RC, Bruce JN, O'Connor KC (2009) The microenvironment of germ cell tumors harbors a prominent antigendriven humoral response. J Immunol 182(5):3310-3317. doi:10.4049/ jimmunol.0803424
56. Yeilding NM, Gerstner C, Kirkwood JM (1992) Analysis of two human monoclonal antibodies against melanoma. Int J Cancer 52(6):967-973 (Pubitemid 23009517)
57. Zhang H, Lake DF, Barbuto JA, Bernstein RM, Grimes WJ, Hersh EM (1995) A human monoclonal antimelanoma singlechain Fv antibody derived from tumor-infiltrating lymphocytes. Cancer Res 55(16):3584-3591
58. Konorza G, Sesterhenn K, Krueger GR, Ablashi DV (1979) Distribution of T- and B-cells and of immunoglobulin-producing cells in tumor tissue of patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol 93(2):195-204 (Pubitemid 9175404)
59. Shigematsu Y, Hanagiri T, Kuroda K, Baba T, Mizukami M, Ichiki Y, Yasuda M, Takenoyama M, Sugio K, Yasumoto K (2009) Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers. Cancer Sci 100(7):1326-1334. doi:10.1111/j.1349-7006. 2009.01181.x
60. Punt CJ, Barbuto JA, Zhang H, Grimes WJ, Hatch KD, Hersh EM (1994) Anti-tumor antibody produced by human tumorinfiltrating and peripheral blood B lymphocytes. Cancer Immunol Immunother 38(4):225-232 (Pubitemid 24108733)
61. Zirakzadeh AA, Marits P, Sherif A, Winqvist O (2013) Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies. J Immunol 190(11):5847-5855. doi:10.4049/jimmunol.1203279
62. Yasuda M, Mizukami M, Hanagiri T, Shigematsu Y, Fukuyama T, Nagata Y, So T, Ichiki Y, Sugaya M, Takenoyama M, Sugio K, Yasumoto K (2006) Antigens recognized by IgG derived from tumor-infiltrating B lymphocytes in human lung cancer. Anticancer Res 26(5A):3607-3611 (Pubitemid 44701546)
63. Mizukami M, Hanagiri T, Yasuda M, Kuroda K, Shigematsu Y, Baba T, Fukuyama T, Nagata Y, So T, Ichiki Y, Sugaya M, Takenoyama M, Sugio K, Yasumoto K (2007) Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice. Cancer Res 67(17):8351-8357 (Pubitemid 47395174)
64. Mizukami M, Hanagiri T, Shigematsu Y, Baba T, Fukuyama T, Nagata Y, So T, Ichiki Y, Sugaya M, Yasuda M, Takenoyama M, Sugio K, Yasumoto K (2006) Effect of IgG produced by tumorinfiltrating B lymphocytes on lung tumor growth. Anticancer Res 26(3A):1827-1831 (Pubitemid 43989439)
65. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N (2009) A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58(10):1535-1544. doi:10.1007/s00262-009-0733-4
66. Gilbert AE, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs DH, Takhar P, Geh JL, Healy C, Harries M, Acland KM, Rudman SM, Beavil RL, Blower PJ, Beavil AJ, Gould HJ, Spicer J, Nestle FO, Karagiannis SN (2011) Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS ONE 6(4):e19330. doi:10.1371/journal.pone.0019330
67. Kobold S, Luetkens T, Cao Y, Bokemeyer C, Atanackovic D (2010) Prognostic and diagnostic value of spontaneous tumor-related antibodies. Clin Dev Immunol. doi:10.1155/2010/721531
68. Fossa A, Berner A, Fossa SD, Hernes E, Gaudernack G, Smeland EB (2004) NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 59(4):440-447 (Pubitemid 38661812)
69. Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, Komukai S, Nakagawa S, Odani S, Fujii H, Hatakeyama K (2004) NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 54(1):95-100. doi:10.1007/s00280-004-0768-3 (Pubitemid 38858372)
70. Suppiah A, Greenman J (2013) Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. World J Gastroenterol 19(29):4651-4670. doi:10.3748/wjg.v19.i29.4651
71. Silina KZP, Ancans G, Kalnina Z, Meistere I, Pismennaya A, Leja M, Line A (2013) Autoantibody biomarkers for early detection and prognosis of gastric cancer. In: 15th international congress of immunology (ICI), Milan, Italy, 22 Aug 2013. Front Immunol conference abstract. doi:10.3389/conf.fimmu.2013.02. 01082
72. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8(1):34-47. doi:10.1038/nri2206
73. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, Correa I, Roberts L, Beddowes E, Koers A, Hobbs C, Ferreira S, Geh JL, Healy C, Harries M, Acland KM, Blower PJ, Mitchell T, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN (2013) IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 123(4):1457-1474. doi:10.1172/JCI65579
74. Fujimoto M, Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Koyanagi I, Aini W, Tsuruyama T, Date H, Haga H (2013) Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. Hum Pathol 44(8):1569-1576. doi:10.1016/j.humpath.2013.01.002
75. Kalnina Z, Silina K, Line A (2008) Autoantibody profiles as biomarkers for response to therapy and early detection of cancer. Curr Canc Ther Rev 4(2):149-156. doi:10.2174/157339408784310160
76. Ladanyi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejos Z, Gaudi I, Dobos J, Timar J (2011) Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother 60(12):1729-1738. doi:10.1007/s00262-011- 1071-x
77. Eiro N, Pidal I, Fernandez-Garcia B, Junquera S, Lamelas ML, del Casar JM, Gonzalez LO, Lopez-Muniz A, Vizoso FJ (2012) Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS ONE 7(12):e52796. doi:10.1371/journal.pone.0052796
78. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH (2012) CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 18(12):3281-3292. doi:10.1158/1078-0432.CCR-12-0234
79. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 4(7):e6412. doi:10.1371/journal.pone.0006412
80. Shi JY, Gao Q, Wang ZC, Zhou J, Wang X, Min ZH, Shi YH, Shi GM, Ding ZB, Ke AW, Dai Z, Qiu SJ, Song K, Fan J (2013) Margin infiltrating CD20+ B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma. Clin Cancer Res. doi:10.1158/1078-0432.CCR-12-3497
81. Shim HS, Byun CS, Bae MK, Lee CY, Park IK, Kim DJ, Chung KY, Lee JG (2011) Prognostic effect of stromal lymphocyte infiltration in thymic carcinoma. Lung Cancer 74(2):338-343. doi:10.1016/j.lungcan.2011.03.008
82. Fang L, Lowther DE, Meizlish ML, Anderson RC, Bruce JN, Devine L, Huttner AJ, Kleinstein SH, Lee JY, Stern JN, Yaari G, Lovato L, Cronk KM, O'Connor KC (2013) The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol 15(11):1479-1490. doi:10.1093/neuonc/not110
83. Rodriguez-Pinto D (2005) B cells as antigen presenting cells. Cell Immunol 238(2):67-75. doi:10.1016/j.cellimm.2006.02.005
84. Ahmadi T, Flies A, Efebera Y, Sherr DH (2008) CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology 124(1):129-140. doi:10.1111/j.1365-2567.2007. 02749.x (Pubitemid 351537580)
85. de Wit J, Souwer Y, Jorritsma T, Klaasse Bos H, ten Brinke A, Neefjes J, van Ham SM (2010) Antigen-specific B cells reactivate an effective cytotoxic T cell response against phagocytosed Salmonella through cross-presentation. PLoS ONE 5(9):e13016. doi:10.1371/journal.pone.0013016
86. Gnjatic S, Atanackovic D, Matsuo M, Jager E, Lee SY, Valmori D, Chen YT, Ritter G, Knuth A, Old LJ (2003) Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J Immunol 170(3):1191-1196 (Pubitemid 36139482)
87. Nielsen JS, Nelson BH (2012) Tumor-infiltrating B cells and T cells: working together to promote patient survival. Oncoimmunology 1(9):1623-1625. doi:10.4161/onci.21650
88. Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH (2009) Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 15(13):4277-4287. doi:10.1158/1078-0432.CCR-09-0537
89. Colonna-Romano G, Bulati M, Aquino A, Pellicano M, Vitello S, Lio D, Candore G, Caruso C (2009) A double-negative (IgD-CD27-) B cell population is increased in the peripheral blood of elderly people. Mech Ageing Dev 130(10):681-690. doi:10.1016/j.mad.2009.08.003
90. Rodriguez-Bayona B, Ramos-Amaya A, Perez-Venegas JJ, Rodriguez C, Brieva JA (2010) Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res Ther 12(3):R108. doi:10.1186/ar3042
91. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner EC, Sanz I (2007) A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 178(10):6624-6633 (Pubitemid 46717447)
92. Bulati M, Buffa S, Candore G, Caruso C, Dunn-Walters DK, Pellicano M, Wu YC, Colonna Romano G (2011) B cells and immunosenescence: a focus on IgG+IgD-CD27- (DN) B cells in aged humans. Ageing Res Rev 10(2):274-284. doi:10.1016/j.arr.2010.12.002
93. Caruso C, Buffa S, Candore G, Colonna-Romano G, Dunn-Walters D, Kipling D, Pawelec G (2009) Mechanisms of immunosenescence. Immun Ageing 6:10. doi:10.1186/1742-4933-6-10
94. Sanz I, Wei C, Lee FE, Anolik J (2008) Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 20(1):67-82. doi:10.1016/j.smim.2007.12.006
95. Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, Li S, Chang AE (2011) Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 17(15):4987-4995. doi:10.1158/1078-0432.CCR-11-0207
96. Kemp TJ, Moore JM, Griffith TS (2004) Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol 173(2):892-899 (Pubitemid 38924262)
97. Hagn M, Schwesinger E, Ebel V, Sontheimer K, Maier J, Beyer T, Syrovets T, Laumonnier Y, Fabricius D, Simmet T, Jahrsdorfer B (2009) Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J Immunol 183(3):1838-1845. doi:10.4049/jimmunol.0901066
98. Hagn M, Sontheimer K, Dahlke K, Brueggemann S, Kaltenmeier C, Beyer T, Hofmann S, Lunov O, Barth TF, Fabricius D, Tron K, Nienhaus GU, Simmet T, Schrezenmeier H, Jahrsdorfer B (2011) Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunol Cell Biol 90(4):457-467. doi:10.1038/icb.2011.64
99. Hagn M, Jahrsdorfer B (2012) Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway. Oncoimmunology 1(8):1368-1375. doi:10.4161/onci.22354
100. Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TF, Beyer T, Reister F, Fabricius D, Lotfi R, Lunov O, Nienhaus GU, Simmet T, Kreienberg R, Moller P, Schrezenmeier H, Jahrsdorfer B (2013) Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res 73(8):2468-2479. doi:10.1158/0008-5472.CAN-12-3450
101. Klinker MW, Lundy SK (2012) Multiple mechanisms of immune suppression by B lymphocytes. Mol Med 18:123-137. doi:10.2119/molmed.2011.00333
102. Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle AM, Thomas JM, Wang E, Marincola FM, Bedognetti D (2011) Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 9:174. doi:10.1186/1479-5876-9-174
103. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res 71(10):3505-3515
104. Horikawa M, Minard-Colin V, Matsushita T, Tedder TF (2011) Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest 121(11):4268-4280. doi:10.1172/JCI59266
105. Lee-Chang C, Bodogai M, Martin-Montalvo A, Wejksza K, Sanghvi M, Moaddel R, de Cabo R, Biragyn A (2013) Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. J Immunol 191(8):4141-4151. doi:10.4049/jimmunol.1300606
106. Bodogai M, Lee Chang C, Wejksza K, Lai J, Merino M, Wersto RP, Gress RE, Chan AC, Hesdorffer C, Biragyn A (2013) Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res 73(7):2127-2138. doi:10.1158/0008-5472.CAN-12- 4184
107. Ruddell A, Harrell MI, Furuya M, Kirschbaum SB, Iritani BM (2011) B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma. Neoplasia 13(8):748-757
108. Yang C, Lee H, Pal S, Jove V, Deng J, Zhang W, Hoon DS, Wakabayashi M, Forman S, Yu H (2013) B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS ONE 8(5):e64159. doi:10.1371/journal.pone.0064159
109. Yang C, Lee H, Jove V, Deng J, Zhang W, Liu X, Forman S, Dellinger TH, Wakabayashi M, Yu H, Pal S (2013) Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS ONE 8(1):e54029. doi:10.1371/journal.pone. 0054029
110. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464(7286):302-305. doi:10.1038/nature08782
111. Ammirante M, Kuraishy AI, Shalapour S, Strasner A, Ramirez-Sanchez C, Zhang W, Shabaik A, Karin M (2013) An IKKal-pha-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev 27(13):1435-1440. doi:10.1101/gad.220202.113
112. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F (2009) Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 348(1-2):9-17. doi:10.1016/j.jim.2009.06.004
113. Koizumi M, Hiasa Y, Kumagi T, Yamanishi H, Azemoto N, Kobata T, Matsuura B, Abe M, Onji M (2013) Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer. PLoS ONE 8(8):e71367. doi:10.1371/journal.pone.0071367
114. Victora GD, Nussenzweig MC (2012) Germinal centers. Annu Rev Immunol 30:429-457. doi:10.1146/annurev-immunol-020711-075032
115. van de Pavert SA, Mebius RE (2010) New insights into the development of lymphoid tissues. Nat Rev Immunol 10(9):664-674. doi:10.1038/nri2832
116. Kain MJ, Owens BM (2013) Stromal cell regulation of homeostatic and inflammatory lymphoid organogenesis. Immunology 140(1):12-21. doi:10.1111/imm.12119
117. Onder L, Danuser R, Scandella E, Firner S, Chai Q, Hehlgans T, Stein JV, Ludewig B (2013) Endothelial cell-specific lymphotoxin-beta receptor signaling is critical for lymph node and high endothelial venule formation. J Exp Med 210(3):465-473. doi:10.1084/jem.20121462
118. McDonald KG, McDonough JS, Newberry RD (2005) Adaptive immune responses are dispensable for isolated lymphoid follicle formation: antigen-naive, lymphotoxin-sufficient B lymphocytes drive the formation of mature isolated lymphoid follicles. J Immunol 174(9):5720-5728 (Pubitemid 40593215)
119. McDonald KG, McDonough JS, Wang C, Kucharzik T, Williams IR, Newberry RD (2007) CC chemokine receptor 6 expression by B lymphocytes is essential for the development of isolated lymphoid follicles. Am J Pathol 170(4):1229-1240. doi:10.2353/ajpath.2007.060817 (Pubitemid 47339331)
120. Marchesi F, Martin AP, Thirunarayanan N, Devany E, Mayer L, Grisotto MG, Furtado GC, Lira SA (2009) CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles. Mucosal Immunol 2(6):486-494. doi:10.1038/mi.2009.113
121. Litsiou E, Semitekolou M, Galani IE, Morianos I, Tsoutsa A, Kara P, Rontogianni D, Bellenis I, Konstantinou M, Potaris K, Andreakos E, Sideras P, Zakynthinos S, Tsoumakidou M (2013) CXCL13 production in B cells via Toll-like receptor/lymphotoxin receptor signaling is involved in lymphoid neogenesis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187(11):1194-1202. doi:10.1164/rccm.201208-1543OC
122. Reisfeld RA, Gillies SD, Mendelsohn J, Varki NM, Becker JC (1996) Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. Cancer Res 56(8):1707-1712 (Pubitemid 26118200)
123. Schrama D, Thor Straten P, Fischer WH, McLellan AD, Brocker EB, Reisfeld RA, Becker JC (2001) Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14(2):111-121 (Pubitemid 32206514)
124. Kim HJ, Kammertoens T, Janke M, Schmetzer O, Qin Z, Berek C, Blankenstein T (2004) Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells. J Immunol 172(7):4037-4047 (Pubitemid 38375215)
125. de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, Cremer I, Fridman WH, Sautes-Fridman C, Dieu-Nosjean MC (2011) Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 71(20):6391-6399. doi:10.1158/0008-5472.CAN-11-0952
126. Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, Mule JJ (2011) Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 179(1):37-45. doi:10.1016/j.ajpath.2011.03.007
127. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mule JJ (2012) 12-Chemokine gene signature identifies lymph nodelike structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2:765. doi:10.1038/srep00765
128. Bergomas F, Grizzi F, Doni A, Pesce S, Laghi L, Allavena P, Mantovani A, Marchesi F (2011) Tertiary intratumor lymphoid tissue in colo-rectal cancer. Cancers 4(1):1-10
129. Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6(3):205-217. doi:10.1038/nri1786 (Pubitemid 43290990)
130. Burrell BE, Ding Y, Nakayama Y, Park KS, Xu J, Yin N, Bromberg JS (2011) Tolerance and lymphoid organ structure and function. Front Immunol 2:64. doi:10.3389/fimmu.2011.00064
131. Katakai T, Nomura T, Gonda H, Sugai M, Agata Y, Nishio A, Masuda T, Sakaguchi S, Shimizu A (2006) Spontaneous largescale lymphoid neogenesis and balanced autoimmunity versus tolerance in the stomach of H+/K+-ATPase-reactive TCR transgenic mouse. J Immunol 177(11):7858-7867 (Pubitemid 44846301)
132. Brown K, Sacks SH, Wong W (2011) Tertiary lymphoid organs in renal allografts can be associated with donor-specific tolerance rather than rejection. Eur J Immunol 41(1):89-96. doi:10.1002/eji.201040759
133. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA (2010) Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328(5979):749-752. doi:10.1126/science.1185837
134. Gottlin EB, Bentley RC, Campa MJ, Pisetsky DS, Herndon JE 2nd, Patz EF Jr (2011) The association of intratumoral germinal centers with early-stage non-small cell lung cancer. J Thorac Oncol 6(10):1687-1690. doi:10.1097/JTO. 0b013e3182217bec
135. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M (1998) Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27(2):407-414. doi:10.1002/hep.510270214 (Pubitemid 28081054)
136. Yu H, Yang J, Jiao S, Wang J (2013) Prognostic value of B lymphocyte infiltration in breast cancer. Nan Fang Yi Ke Da Xue Xue Bao 33(5):750-755
137. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS (2009) Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15(20):6412-6420. doi:10.1158/1078-0432.CCR-09-1438
138. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Mino-Kenudson M, Giovannucci EL, Meyerhardt JA, Fuchs CS (2010) Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol 105(2):420-433. doi:10.1038/ajg.2009.578
139. Cipponi A, Mercier M, Seremet T, Baurain JF, Theate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N (2012) Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 72(16):3997-4007. doi:10.1158/0008-5472.CAN-12-1377
140. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, Lebecque S, Fridman WH, Cadranel J (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26(27):4410-4417. doi:10.1200/JCO.2007.15.0284
141. Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, Garrido I, Girard JP (2012) High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumorinfiltrating lymphocytes. Oncoimmunology 1(6):829-839. doi:10.4161/onci.20492
142. Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, Validire P, Remark R, Hammond SA, Cremer I, Damotte D, Fridman WH, Sautes-Fridman C, Dieu-Nosjean MC (2013) Dendritic cells in tumor-associated tertiary lymphoid structures license the positive prognostic value of tumor-infiltrating CD8 +T cells. Cancer Res. doi:10.1158/0008-5472.CAN-13-1342
143. Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I, Girard JP (2013) High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin beta-producing dendritic cells in human breast cancer. J Immunol 191(4):2001-2008. doi:10.4049/jimmunol.1300872
144. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautes-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L (2012) Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 1(8):1323-1343. doi:10.4161/onci.22009
145. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL Jr (2012) Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72(5):1070-1080. doi:10.1158/0008- 5472.CAN-11-3218
146. Varella AD, Bandiera DC, de Amorim AR Sr, Calvis LA, Santos IO, Escaleira N, Gentil F (1981) Treatment of disseminated malignant melanoma with high-dose oral BCG. Cancer 48(6):1353-1362 (Pubitemid 11042587)
147. Chang SG, Lee SJ, Huh JS, Lee JH (2001) Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy. Oncol Rep 8(2):257-261
148. Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein LC, El-Naggar A, Badoual C, Fridman WH, White JM, Hadden JW (2012) Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother 61(6):771-782. doi:10.1007/s00262-011-1134-z
149. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman SM (1997) Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 28(3):321-331 (Pubitemid 27106085)
150. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B (2006) NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 125(3):451-458 (Pubitemid 43327717)
151. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM (2012) Leucocyte composition of human breast cancer. Proc Natl Acad Sci USA 109(8):2796-2801. doi:10.1073/pnas.1104303108
152. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothe F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K (2013) CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 123(7):2873-2892. doi:10.1172/JCI67428
153. Gunderson AJ, Coussens LM (2013) B cells and their mediators as targets for therapy in solid tumors. Exp Cell Res. doi:10.1016/j.yexcr.2013.03.005
154. Spaner DE, Bahlo A (2011) B lymphocytes in cancer immunology. In: Medin J, Fowler DH (eds) Experimental and applied immunotherapy, vol XVIII. Humana Press, New York, pp 37-57. doi:10.1007/978-1-60761-980-2-2
155. Barbera-Guillem E, Nelson MB, Barr B, Nyhus JK, May KF Jr, Feng L, Sampsel JW (2000) B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 48(10):541-549 (Pubitemid 30004488)
156. Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF (2004) Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 15(7):1109-1114. doi:10.1093/annonc/mdh280 (Pubitemid 39099116)
157. Naslund TI, Gehrmann U, Gabrielsson S (2013) Cancer immunotherapy with exosomes requires B-cell activation. Oncoimmunology 2(6):e24533. doi:10.4161/onci.24533
158. Naslund TI, Gehrmann U, Qazi KR, Karlsson MC, Gabrielsson S (2013) Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol 190(6):2712-2719. doi:10.4049/jimmunol.1203082
159. Kornbluth RS, Stempniak M, Stone GW (2012) Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. Int Rev Immunol 31(4):279-288. doi:10.3109/08830185.2012.703272
160. Jackaman C, Cornwall S, Graham PT, Nelson DJ (2011) CD40-activated B cells contribute to mesothelioma tumor regression. Immunol Cell Biol 89(2):255-267. doi:10.1038/icb.2010.88
161. Baeten CI, Castermans K, Hillen HF, Griffioen AW (2006) Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. Clin Gastroenterol Hepatol 4(11):1351-1357. doi:10.1016/j.cgh.2006.08. 005 (Pubitemid 44716741)
162. Dong J, Li J, Liu SM, Feng XY, Chen S, Chen YB, Zhang XS (2013) CD33(+)/p-STAT1(+) double-positive cell as a prognostic factor for stage IIIa gastric cancer. Med Oncol 30(1):442. doi:10.1007/s12032-012-0442-2
163. Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV (2009) Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMCGastroenterol 9:65
164. Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, Kim WH (2008) Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 99(10):1704-1711. doi:10.1038/sj.bjc.6604738
165. Liang J, Ding T, Guo ZW, Yu XJ, Hu YZ, Zheng L, Xu J (2013) Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer 109(4):1031-1039. doi:10.1038/bjc.2013.390
166. Goeppert B, Frauenschuh L, Zucknick M, Stenzinger A, Andrulis M, Klauschen F, Joehrens K, Warth A, Renner M, Mehrabi A, Hafezi M, Thelen A, Schirmacher P, Weichert W (2013) Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer 109(10):2665-2674. doi:10.1038/bjc.2013.610
167. Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G (2009) Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 9:292. doi:10.1186/1471-2407-9-292
168. Distel LV, Fickenscher R, Dietel K, Hung A, Iro H, Zenk J, Nkenke E, Buttner M, Niedobitek G, Grabenbauer GG (2009) Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol 45(10):e167-e174. doi:10.1016/j.oraloncology.2009.05.640
169. Esteban F, Redondo M, Delgado M, Garrido F, Ruiz-Cabello F (1996) MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up. Br J Cancer 74(11):1801-1804 (Pubitemid 26401902)
170. Pelletier MP, Edwardes MD, Michel RP, Halwani F, Morin JE (2001) Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 44(3):180-188 (Pubitemid 32538769)
171. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14(16):5220-5227. doi:10.1158/1078-0432.CCR-08-0133
172. Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund LT (2010) The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma. APMIS 118(5):371-382. doi:10.1111/j.1600-0463.2010.02609.x
173. Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, Berglund A, Lambe M, Holmberg L, Ekman S, Bergqvist M, Ponten F, Cadenas C, Marchan R, Hengstler JG, Rahnenfuhrer J, Micke P (2013) The prognostic relevance of tumourinfiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett 333(2):222-228. doi:10.1016/j.canlet.2013.01.036
174. Meyer S, Fuchs TJ, Bosserhoff AK, Hofstadter F, Pauer A, Roth V, Buhmann JM, Moll I, Anagnostou N, Brandner JM, Ikenberg K, Moch H, Landthaler M, Vogt T, Wild PJ (2012) A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS ONE 7(6):e38222. doi:10.1371/journal.pone.0038222
175. Stumpf M, Hasenburg A, Riener MO, Jutting U, Wang C, Shen Y, Orlowska-Volk M, Fisch P, Wang Z, Gitsch G, Werner M, Lassmann S (2009) Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer 101(9):1513-1521. doi:10.1038/sj.bjc.6605274
176. Ancuta E, Ancuta C, Zugun-Eloae F, Iordache C, Chirieac R, Carasevici E (2009) Predictive value of cellular immune response in cervical cancer. Rom J Morphol Embryol 50(4):651-655
177. Nedergaard BS, Ladekarl M, Nyengaard JR, Nielsen K (2008) A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol Oncol 108(1):106-111. doi:10.1016/j.ygyno.2007.08.089 (Pubitemid 350299430)
178. Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R (2005) Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 25(6C):4435-4438 (Pubitemid 41729492)
179. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT (2012) High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator. Oncoimmunology 1(1):75-77. doi:10.4161/onci.1.1.17825